Persistence of Lymphocytotoxic Antibodies in Patients in the Trial to Reduce Alloimmunization to Platelets: Implications for Using Modified Blood Products

Sherrill J. Slichter, Douglas Bolgiano, Kuo Jang Kao, Thomas Stephen Kickler, Janice McFarland, Jeffrey McCullough, Robert Woodson

Research output: Contribution to journalArticle

Abstract

Patients with acute myelogenous leukemia undergoing induction chemotherapy have significant decreases in alloimmune platelet refractoriness if they receive filter-leukoreduced or UV-B-irradiated vs standard platelet transfusions (3%-5% vs 13%, respectively; P ≤ .03) with no differences among the treated platelet arms (Trial to Reduce Alloimmunization to Platelets). Therefore, measuring antibody persistence might identify the best platelets for transfusion. Lymphocytotoxic (LCT) antibody duration was evaluated for association with patient age, sex, prior transfusion and pregnancy history, study-assigned platelet transfusions, and percentage LCT panel reactive antibodies. During the Trial to Reduce Alloimmunization to Platelets, 145 patients became antibody positive; and 81 (56%) of them subsequently became antibody negative. Using Kaplan-Meier estimates, projected antibody loss was 73% at 1 year. Major factors associated with antibody persistence were prior pregnancy and percentage panel reactive antibody positivity, whereas neither the assigned type of platelets transfused during the 8 weeks of the trial nor prior transfusion history was predictive. After 5 to 8 weeks, the number and type of blood products transfused had no effect on either antibody development or loss. A majority of patients with acute myelogenous leukemia who develop LCT antibodies during induction chemotherapy will lose their antibodies within 4 months regardless of the type or number of blood products they receive.

Original languageEnglish (US)
Pages (from-to)102-110
Number of pages9
JournalTransfusion Medicine Reviews
Volume25
Issue number2
DOIs
StatePublished - Apr 2011

Fingerprint

Antilymphocyte Serum
Platelets
Blood
Blood Platelets
Antibodies
Platelet Transfusion
Induction Chemotherapy
Chemotherapy
Acute Myeloid Leukemia
History
Reproductive History
Kaplan-Meier Estimate
Pregnancy

ASJC Scopus subject areas

  • Hematology
  • Biochemistry, medical
  • Clinical Biochemistry

Cite this

Persistence of Lymphocytotoxic Antibodies in Patients in the Trial to Reduce Alloimmunization to Platelets : Implications for Using Modified Blood Products. / Slichter, Sherrill J.; Bolgiano, Douglas; Kao, Kuo Jang; Kickler, Thomas Stephen; McFarland, Janice; McCullough, Jeffrey; Woodson, Robert.

In: Transfusion Medicine Reviews, Vol. 25, No. 2, 04.2011, p. 102-110.

Research output: Contribution to journalArticle

Slichter, Sherrill J. ; Bolgiano, Douglas ; Kao, Kuo Jang ; Kickler, Thomas Stephen ; McFarland, Janice ; McCullough, Jeffrey ; Woodson, Robert. / Persistence of Lymphocytotoxic Antibodies in Patients in the Trial to Reduce Alloimmunization to Platelets : Implications for Using Modified Blood Products. In: Transfusion Medicine Reviews. 2011 ; Vol. 25, No. 2. pp. 102-110.
@article{51501b0f841d4a3d993d814e6766cb09,
title = "Persistence of Lymphocytotoxic Antibodies in Patients in the Trial to Reduce Alloimmunization to Platelets: Implications for Using Modified Blood Products",
abstract = "Patients with acute myelogenous leukemia undergoing induction chemotherapy have significant decreases in alloimmune platelet refractoriness if they receive filter-leukoreduced or UV-B-irradiated vs standard platelet transfusions (3{\%}-5{\%} vs 13{\%}, respectively; P ≤ .03) with no differences among the treated platelet arms (Trial to Reduce Alloimmunization to Platelets). Therefore, measuring antibody persistence might identify the best platelets for transfusion. Lymphocytotoxic (LCT) antibody duration was evaluated for association with patient age, sex, prior transfusion and pregnancy history, study-assigned platelet transfusions, and percentage LCT panel reactive antibodies. During the Trial to Reduce Alloimmunization to Platelets, 145 patients became antibody positive; and 81 (56{\%}) of them subsequently became antibody negative. Using Kaplan-Meier estimates, projected antibody loss was 73{\%} at 1 year. Major factors associated with antibody persistence were prior pregnancy and percentage panel reactive antibody positivity, whereas neither the assigned type of platelets transfused during the 8 weeks of the trial nor prior transfusion history was predictive. After 5 to 8 weeks, the number and type of blood products transfused had no effect on either antibody development or loss. A majority of patients with acute myelogenous leukemia who develop LCT antibodies during induction chemotherapy will lose their antibodies within 4 months regardless of the type or number of blood products they receive.",
author = "Slichter, {Sherrill J.} and Douglas Bolgiano and Kao, {Kuo Jang} and Kickler, {Thomas Stephen} and Janice McFarland and Jeffrey McCullough and Robert Woodson",
year = "2011",
month = "4",
doi = "10.1016/j.tmrv.2010.11.002",
language = "English (US)",
volume = "25",
pages = "102--110",
journal = "Transfusion Medicine Reviews",
issn = "0887-7963",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Persistence of Lymphocytotoxic Antibodies in Patients in the Trial to Reduce Alloimmunization to Platelets

T2 - Implications for Using Modified Blood Products

AU - Slichter, Sherrill J.

AU - Bolgiano, Douglas

AU - Kao, Kuo Jang

AU - Kickler, Thomas Stephen

AU - McFarland, Janice

AU - McCullough, Jeffrey

AU - Woodson, Robert

PY - 2011/4

Y1 - 2011/4

N2 - Patients with acute myelogenous leukemia undergoing induction chemotherapy have significant decreases in alloimmune platelet refractoriness if they receive filter-leukoreduced or UV-B-irradiated vs standard platelet transfusions (3%-5% vs 13%, respectively; P ≤ .03) with no differences among the treated platelet arms (Trial to Reduce Alloimmunization to Platelets). Therefore, measuring antibody persistence might identify the best platelets for transfusion. Lymphocytotoxic (LCT) antibody duration was evaluated for association with patient age, sex, prior transfusion and pregnancy history, study-assigned platelet transfusions, and percentage LCT panel reactive antibodies. During the Trial to Reduce Alloimmunization to Platelets, 145 patients became antibody positive; and 81 (56%) of them subsequently became antibody negative. Using Kaplan-Meier estimates, projected antibody loss was 73% at 1 year. Major factors associated with antibody persistence were prior pregnancy and percentage panel reactive antibody positivity, whereas neither the assigned type of platelets transfused during the 8 weeks of the trial nor prior transfusion history was predictive. After 5 to 8 weeks, the number and type of blood products transfused had no effect on either antibody development or loss. A majority of patients with acute myelogenous leukemia who develop LCT antibodies during induction chemotherapy will lose their antibodies within 4 months regardless of the type or number of blood products they receive.

AB - Patients with acute myelogenous leukemia undergoing induction chemotherapy have significant decreases in alloimmune platelet refractoriness if they receive filter-leukoreduced or UV-B-irradiated vs standard platelet transfusions (3%-5% vs 13%, respectively; P ≤ .03) with no differences among the treated platelet arms (Trial to Reduce Alloimmunization to Platelets). Therefore, measuring antibody persistence might identify the best platelets for transfusion. Lymphocytotoxic (LCT) antibody duration was evaluated for association with patient age, sex, prior transfusion and pregnancy history, study-assigned platelet transfusions, and percentage LCT panel reactive antibodies. During the Trial to Reduce Alloimmunization to Platelets, 145 patients became antibody positive; and 81 (56%) of them subsequently became antibody negative. Using Kaplan-Meier estimates, projected antibody loss was 73% at 1 year. Major factors associated with antibody persistence were prior pregnancy and percentage panel reactive antibody positivity, whereas neither the assigned type of platelets transfused during the 8 weeks of the trial nor prior transfusion history was predictive. After 5 to 8 weeks, the number and type of blood products transfused had no effect on either antibody development or loss. A majority of patients with acute myelogenous leukemia who develop LCT antibodies during induction chemotherapy will lose their antibodies within 4 months regardless of the type or number of blood products they receive.

UR - http://www.scopus.com/inward/record.url?scp=79952693532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952693532&partnerID=8YFLogxK

U2 - 10.1016/j.tmrv.2010.11.002

DO - 10.1016/j.tmrv.2010.11.002

M3 - Article

C2 - 21345638

AN - SCOPUS:79952693532

VL - 25

SP - 102

EP - 110

JO - Transfusion Medicine Reviews

JF - Transfusion Medicine Reviews

SN - 0887-7963

IS - 2

ER -